Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.
about
Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortalityAntifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance PPerformance of CHROMAGAR candida and BIGGY agar for identification of yeast speciesCandidaDB: a genome database for Candida albicans pathogenomicsRisk factors for fatal candidemia caused by Candida albicans and non-albicans Candida speciesEpidemiological trends in nosocomial candidemia in intensive careHighly variable rates of genome rearrangements between hemiascomycetous yeast lineagesAntifungal resistance in pathogenic fungiAntifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobiaComparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces.Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.Rapid identification of Candida species by using nuclear magnetic resonance spectroscopy and a statistical classification strategy.Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III.Serum repressing efflux pump CDR1 in Candida albicans.Mannose binding lectin plays a crucial role in innate immunity against yeast by enhanced complement activation and enhanced uptake of polymorphonuclear cells.Caspofungin-Non-Susceptible Candida orthopsilosis Isolated from Onychomycosis in Iran.A Review of Diagnostic Methods for Invasive Fungal Diseases: Challenges and Perspectives.Candidemia distribution, associated risk factors, and attributed mortality at a university-based medical center.Efg1 involved in drug resistance by regulating the expression of ERG3 in Candida albicans.Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada.Novel fluorescent broth microdilution method for fluconazole susceptibility testing of Candida albicans.Trends in antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A reference method.Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility.Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates.In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum.Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout miceIn vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.Comparative evaluation of a new fluorescent carboxyfluorescein diacetate-modified microdilution method for antifungal susceptibility testing of Candida albicans isolates.Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.Comparison of human and soil Candida tropicalis isolates with reduced susceptibility to fluconazoleIn vitro antifungal susceptibility testing.Antifungal resistance among Candida species.Rationale for combination antifungal therapy.A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America.
P2860
Q24530412-06EDE9F1-E1EF-4C70-AC11-295ACFFE83AEQ24535844-2D6E1592-129A-4C81-BE25-97306EFDE075Q24797201-3ADFBE90-BD95-42DB-BCA0-C21DE61B9DBFQ24797602-D7A5C093-0A75-41F3-8418-052536A8CFFCQ24799296-361CC9B9-198B-4ECD-BB09-E4B715AA11D7Q25255762-E53C0F62-9EEF-4AC4-A395-602FD1E14CC1Q25256551-06B53E3D-214C-49E4-9984-D47C65D5E9DAQ28208165-57DB931B-4377-4764-9E7B-5E55BDCEFD8BQ30452376-3095A54B-9355-41DE-A5C6-047B50D87DA4Q30452998-75E4615E-60E9-4CAB-BBAA-C635A198689DQ30453032-2A768E87-A13C-45D9-8C6A-D66C6D68F943Q30453797-E34978C8-2B09-4841-91FA-685260566DB6Q30799502-407C50BB-134A-4227-B980-641E088D55C3Q31058690-D2BC31BB-B9DD-42CF-8317-1BD7789EB424Q33183542-5DAC7817-B7F0-4E47-B446-C8270C00742AQ33188024-577467B0-949C-4D8C-976E-CF80D5CF7519Q33210615-BC922476-71C4-409E-BEEB-3709A1FB3346Q33250096-9C699DBF-7ABF-4183-B59F-424FA5A422CEQ33394366-3CA33D3B-5F39-4893-BB49-25592F3608D1Q33596063-306E326D-A1B1-4B58-B57D-3B559E7F5019Q33732549-72B9D222-FF72-4071-8F08-2094B5AFF24DQ33835893-BA5CE96C-BC71-4557-91EA-290733CE492EQ33858493-87E1EFD5-FFA0-443F-A482-4F99783EF2C3Q33938082-CDE527C3-C9FA-4A24-99E6-4E8D10350235Q33971521-CB964B68-4DFE-48D6-BC42-4703A55ADC84Q33973011-B0C6ECA1-8899-4586-8423-A70116742A7DQ33974143-47E9BCD1-5F25-4F29-899E-D90EA60EEB9EQ34042232-3E872C33-3F79-42CF-80AE-14F0A7132936Q34045265-91F18F03-43C9-46F5-841E-7A1F218F3664Q34106775-54EA16F7-0522-4A07-9184-ADC0D8A0A207Q34107525-27332813-14C4-4F93-90F9-A36AA9F272FEQ34142406-64E05A51-029D-41DC-ABAF-D233E1617527Q34143149-CC6D6D8C-6B4A-4906-89B8-8851CC4FDE2EQ34202154-DE61696D-6CA5-4593-BF20-57C73C723CD8Q34228354-60824715-F603-4923-BCD0-7AFFD7D7ADE1Q34230214-F18BA5E4-61C6-48F0-9E8B-7B48783F5461Q34335217-F54A36D8-D94F-4593-944F-0EC14D89646BQ34335225-E428C0C0-10F1-44C0-A942-8DCA912E1CF0Q34335236-5E30A567-AA7C-4532-BA91-3700767352DFQ34335250-5EDF2E47-710A-44AA-8487-A85404D46CDC
P2860
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Bloodstream infections due to ...... and Latin America, 1997-1998.
@ast
Bloodstream infections due to ...... and Latin America, 1997-1998.
@en
type
label
Bloodstream infections due to ...... and Latin America, 1997-1998.
@ast
Bloodstream infections due to ...... and Latin America, 1997-1998.
@en
prefLabel
Bloodstream infections due to ...... and Latin America, 1997-1998.
@ast
Bloodstream infections due to ...... and Latin America, 1997-1998.
@en
P2093
P2860
P1476
Bloodstream infections due to ...... and Latin America, 1997-1998.
@en
P2093
M A Pfaller
R J Hollis
S A Messer
P2860
P304
P356
10.1128/AAC.44.3.747-751.2000
P407
P577
2000-03-01T00:00:00Z